Press Release

June 12, 2023
Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

New Launch of Mounjaro® 7.5 mg /10 mg /12.5 mg /15 mg Ateos®,the World’s First Sustained Release GIP/GLP-1 Receptor Agonist

Full Lineup Now Available
June 12, 2023 - Eli Lilly Japan K.K. (Head Office: Kobe, Japan, Representative Director and President:
Simone Thomsen, hereinafter called “Eli Lilly Japan”) and Mitsubishi Tanabe Pharma Corporation(Head Office: Osaka, Japan, Representative Director: Akihiro Tsujimura, hereinafter called “MTPC”)
announced that “Mounjaro® subcutaneous injection 7.5 mg /10 mg /12.5 mg /15 mg ATEOS®” (Nonproprietary name: Tirzepatide, hereinafter referred called “Mounjaro”), the following sustained release
GIP/GLP-1 receptor agonists, was launched in Japan today.
Of the six dosage standards for the Mounjaro® subcutaneous injection, two were launched ahead of timeon April 18 this year, namely, the starting dose (2.5 mg) and the maintenance dose (5 mg). However, on
this occassion, Eli Lilly Japan and MTPC have now added the remaining four higher dose standards (7.5mg, 10 mg, 12.5 mg, and 15 mg) to complete the Mounjaro lineup.

As the world’s first sustained release GIP (glucose-dependent insulinotropic polypeptide) and GLP-1(glucagon-like peptide-1) receptor agonist, Mounjaro activates two receptors: GIP and GLP-1. Although
the structure of Mounjaro is a single molecule based on the natural GIP peptide sequence, it has been
modified to also bind to the GLP-1 receptor, and selectively acts for a long time to improve blood
glucose.
Mounjaro is administered once weekly by subcutaneous injection with a single-use autoinjector device(ATEOS). Using a special pen injector with a pre-installed needle, the needle is automatically inserted

1/3under the skin by pressing the injection button, and a single dose of the filled drug is injected. The patientdoes not need to set the dose or handle the needle.
For adults, the drug tirzepatide is usually used with a starting dose of 2.5 mg once a week administeredfor 4 weeks, and then increased to a maintenance dose of 5 mg once a week. It is a drug whose dosage
can be increased or decreased according to each patient’s condition, and if the efficacy of 5 mg isinsufficient, the dose can be increased in 2.5 mg increments at intervals of 4 weeks or more, and up to15 mg can be used once a week.
Eli Lilly Japan holds the manufacturing and marketing approval for Mounjaro, while MTPC is responsible
for sales and distribution. Eli Lilly Japan and MTPC will jointly provide information to healthcare
professionals. Through this product lineup, both Eli Lilly Japan and MTPC will strive to provide appropriate
information so that both companies can contribute to improving the lives of people living with type 2diabetes mellitus.

Reference Information

Product Summary
Product Name

Non-proprietary Name
Indications
Dosage andAdministration

Date of acquisition ofmanufacturing andmarketing approval
Date of NHI price listing
Date of launch
Drug price

Manufacturer anddistributor
Distributor

Mounjaro® subcutaneous injection 7.5 mg ATEOS®
Mounjaro® subcutaneous injection 10 mg ATEOS®
Mounjaro® subcutaneous injection 12.5 mg ATEOS®
Mounjaro® subcutaneous injection 15 mg ATEOS®
Tirzepatide
Type 2 diabetes
For adults, the usual maintenance dose of Tirzepatide is 5 mg once a weekby subcutaneous injection. However, start with 2.5 mg once weekly andincrease to 5 mg once weekly after 4 weeks.
The dosage may be adjusted according to the patient's condition, but if theeffect is insufficient with 5 mg once a week, the dosage can be increased by
2.5 mg at intervals of 4 weeks or longer. However, the maximum dosage
should be up to 15 mg once weekly.
September 26, 2022
March 15, 2023
June 12, 2023
Mounjaro® subcutaneous injection 7.5 mg ATEOS® 0.5mL 1kit: 5,772 yen
Mounjaro® subcutaneous injection 10 mg ATEOS® 0.5mL 1kit: 7,696 yen
Mounjaro® subcutaneous injection 12.5 mg ATEOS® 0.5mL 1kit: 9,620 yen
Mounjaro® subcutaneous injection 15 mg ATEOS® 0.5mL 1kit: 11,544 yen
Eli Lilly Japan K.K.
Mitsubishi Tanabe Pharma Corporation

2/3

Product Pictures

Mounjaro® subcutaneous injection 7.5 mg ATEOS

Mounjaro® subcutaneous injection 10 mg ATEOS

Mounjaro® subcutaneous injection 12.5 mg ATEOS

Mounjaro® subcutaneous injection 15 mg ATEOS

About Eli Lilly Japan
Eli Lilly Japan K.K. is a subsidiary of US-based Eli Lilly and Company. It contributes to medical
treatment in Japan through the development, manufacture, import and sale of innovative
pharmaceutical products that enable people to live longer, healthier, and more fulfilling lives, focusing
on the therapeutic areas such as cancer, diabetes, musculoskeletal diseases, central nervous systemdiseases, autoimmune diseases, growth disorder, and pain. For more information, visit
http://www.lilly.co.jp
About Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG),
is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethicalpharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s
pharmaceutical industry. MCG has positioned health care as its strategic focus in its management
policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that
end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes
and kidney, and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment
satisfaction by identifying patient populations with high potential for efficacy and safety. In addition,
MTPC is working to develop “around the pill solutions” to address specific patient concerns based ontherapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention ofaggravation and prognosis. For more information, go to https://www.mt-pharma.co.jp/e/3/3